The AJMC® Psoriasis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin disease, which tends to go through cycles where it flares and goes into remission.
January 15th 2025
Study highlights the efficacy and safety of tildrakizumab in improving physical, psychological, and social aspects of quality of life for patients with psoriasis.
A panel of experts discuss their personalized approaches to treating patients with psoriasis and comorbidities such as metabolic syndrome.
No Association Between Biologics to Treat Psoriasis and Psychiatric Illness